Deqi Pharmaceuticals: Plan to repurchase shares for a maximum total cost of HK$50 million.

On the morning of June 25th, Deqi Pharmaceuticals announced on the Hong Kong Stock Exchange that on June 24th, 2026, the board of directors had resolved to utilize the share buyback mandate, and to repurchase shares in the open market at a maximum total cost of 50 million Hong Kong dollars, subject to market conditions. The board of directors may subsequently cancel the repurchased shares or hold them as treasury shares based on market conditions at the time of repurchase and the capital management needs of the group. The company will provide funds for the proposed share buyback from its internal resources.